No Data
Shenzhen Chipscreen Biosciences (688321.SH): The clinical trial application for Sidabonan has been accepted.
On November 27, Gelonghui reported that shenzhen chipscreen biosciences (688321.SH) announced that it recently received the "Acceptance Notice" for clinical trials of domestically produced pharmaceuticals issued by the National Medical Products Administration's Drug Evaluation Center, and the clinical trial application for chidamide has been accepted by the Drug Review Center of the National Medical Products Administration. Chidamide (brand name "Epidaza") is a national Class 1 innovative drug, uniquely discovered by the company as a new molecular entity with a novel mechanism. As the only orally available subtype-selective histone deacetylase (HDAC) inhibitor in the field, chidamide is effective against tumors.
No money again! Shenzhen Chipscreen Biosciences has "burned" 0.9 billion in R&D expenses over three years and plans to raise another 0.96 billion, nearly 30% of which will be used to supplement cash flow.
shenzhen chipscreen biosciences announced a plan for private placement, planning to raise 0.96 billion yuan, with 0.71 billion yuan for innovative drug research and development, and 0.25 billion yuan for supplementary working capital, reaching a replenishment ratio of 26.04%; Multiple research pipelines continue to burn money for shenzhen chipscreen biosciences, with a total research and development expense of 0.927 billion yuan from 2021 to 2023, currently 17 indication pipelines are in clinical trial stage.
Shenzhen Chipscreen Biosciences Seeks 960 Million Yuan From Share Issuance
Star Evening News | kbc corporation,ltd. affiliated companies' silicon-based anode series products have formed bulk supply. shenzhen chipscreen biosciences plans to raise no more than 0.96 billion yuan through a private placement.
1. Polymax Materials' shareholder plans to reduce its shareholding by no more than 3% of the company's shares; 2. Micronano intends to repurchase shares ranging from 40 million yuan to 80 million yuan; 3. Beijing Hotgen Biotech Co.,Ltd. plans to repurchase shares at a range of 58 million yuan to -0.1 billion yuan; 4. Suzhou Hyc Technology plans to repurchase shares at a range of 25 million yuan to -50 million yuan.
Retail Investors Among Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 3.8% Last Week
Express News | The Phase III Clinical Trial Application for First-Line Treatment of Extensive Disease Small Cell Lung Cancer With Chiauranib Has Been Approved
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 30% Share Price Surge Not Quite Adding UpNo Data
No Data
